Dermatology

Novel inhibitors of kallikrein proteases and uses thereof

Use of coumarin derivatives for the preparation of drugs for treating skin diseases

Use of serine protease inhibitors in the treatment of skin diseases

NCT05642208 – Dupilumab Step-down Strategy to Maintain Remission in Adult and Adolescents Patients With Atopic Dermatitis

Patient cohort

Novel inhibitors of kallikrein proteases and uses thereof

Use of coumarin derivatives for the preparation of drugs for treating skin diseases

Use of serine protease inhibitors in the treatment of skin diseases

NCT05642208 – Dupilumab Step-down Strategy to Maintain Remission in Adult and Adolescents Patients With Atopic Dermatitis

Patient cohort

NCT05370235 – Phase IIa open-label study aimed at evaluating the safety and efficacy of subcutaneous afamelanotide implants in patients with Xeroderma Pigmentosum C and V (XPC and XPV).

NCT04980638 – Intraamniotic Administrations of ER004 to Male Subjects With X-linked Hypohidrotic Ectodermal Dysplasia

EGFR inhibitors for treating keratodermas

Topical use of erlotinib for treating keratodermas in children

cKLK5-/-mouse model

cSPINK5-/-mice

DNA – fibroblasts – Skin biopsies from patients with NS

Immortalized keratinocytes

Screening for KLK5 specific inhibitors – Screening for drugs blocking overexpressed pro-inflammatory cytokines

180 patient cohort (pediatric and adult)

Novel benzimidamides compounds comprising an oxabonirin ring

Novel inhibitors of kallikrein proteases and uses thereof

Use of coumarin derivatives for the preparation of drugs for treating skin diseases

Use of IL-36 inhibitors for the treatment of Netherton syndrome

Use of serine protease inhibitors in the treatment of skin diseases

NCT04244006 – A randomized double-blinded pilot study of the efficacy and safety of dupilumab versus placebo in patients with Netherton syndrome

NCT05211830 – A Phase I/II Multicenter Randomized Double-blind Placebo Within-patient Controlled First-in-human (FIH) Proof of Concept (PoC) Study to Evaluate the Safety and Efficacy of Topically Applied SXR1096 Cream in Patients With Netherton Syndrome (NS)

NCT04853667 – Improve Adherence to Weak or Strong Opioid Analgesics at the Time of Care in Children With Hereditary Epidermolysis Bullosa

NCT05651607 – Evaluation of the Efficacy of CANNABIDIOL on the Pruritus in Children With Hereditary Epidermolysis Bullosa

NCT05248503 – Impact of Complex Care Training of Hereditary Epidermolysis Bullosa on Caregiver Burden (FIREB)

DNA – Fibrobastes – Skin biopsies samples from patients with DD

Immortalized keratinocytes

50 patient cohort

cCOL7A1-/- KO mice/KI mice humanized mouse models

Exon skipping (GeneGraft protocol) – Equivalent skin (dermis-epidermis) model for grafting on mice-COL7A1 Elisa test

Fibroblasts from patients

Immortalized keratinocytes – rCOL7A1 immortalized cells (RDEB)

180 patients with RDEB

Patient cohort – RDEB

Patient cohort – RDEB

Exon skipping strategy for Dystrophic Epidermolysis bullosa (DEB) using triclyclo DNA antisense oligonucleotides targeting exons of COL7A1

NCT04908215 – A Randomised Double-Blind Vehicle-Controlled Phase 2 Study of Topically Applied INM-755 (Cannabinol) Cream in Patients With Epidermolysis Bullosa

NCT04186650 – Ex Vivo Gene Therapy Clinical Trial for RDEB Using Genetically Corrected Autologous Skin Equivalent Grafts

NCT05464381 – Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III Cross-over)

NCT04908215 – A Randomised Double-Blind Vehicle-Controlled Phase 2 Study of Topically Applied INM-755 (Cannabinol) Cream in Patients With Epidermolysis Bullosa

NCT02470689 – Diacerin for the Treatment of Epidermolysis Bullosa Simplex

NCT04908215 – A Randomised Double-Blind Vehicle-Controlled Phase 2 Study of Topically Applied INM-755 (Cannabinol) Cream in Patients With Epidermolysis Bullosa

Methods and compositions for promoting wound healing in subject suffering from ectodermal dysplasias

NCT05378932 – Impact of Dysregulation of Core Body Temperature on Sleep in Patients With Hypohidrotic Ectodermal Dysplasia

>20 patient cohort and patient-relative cohort